Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Corey

Showing results (421-430 of 551) with videos related to

Pageof 56
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 3, 2022
Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/RitonavirEmily S Ford, William Simmons, Ellora N Karmarkar, et al.
Scientific Reports|February 9, 2020
HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine RegimensXiaoying Shen, Fatima Laher, Zoe Moodie, et al.
Medrxiv : the Preprint Server for Health Sciences|November 1, 2024
Safety and implementation of a phase 1 randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newbornsAvy Violari, Kennedy Otwombe, William Hahn, et al.
Cell Host & Microbe|September 13, 2019
A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV ChallengeAmarendra Pegu, Bhavesh Borate, Yunda Huang, et al.
Frontiers in Immunology|April 10, 2026
Profiling of SARS-CoV-2 virus shedding, antibody neutralization, and T-cell receptor repertoires in a large, multi-center cohort of young adults with varied prior exposuresAndrew Fiore-Gartland, Koshlan Mayer-Blackwell, James Stray, et al.
The Lancet. HIV|October 3, 2020
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyLindsey R Baden, Daniel J Stieh, Michal Sarnecki, et al.
Nature Communications|November 28, 2023
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01Yunda Huang, Lily Zhang, Shelly Karuna, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2006
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialNina D Russell, Barney S Graham, Michael C Keefer, et al.
Ebiomedicine|February 2, 2024
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trialMaurine D Miner, Allan deCamp, Nicole Grunenberg, et al.
Plos Medicine|November 15, 2017
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialKenneth H Mayer, Kelly E Seaton, Yunda Huang, et al.
Pageof 56

Showing results (421-430 of 551) with videos related to

Sort By:
Pageof 56
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 3, 2022
Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/RitonavirEmily S Ford, William Simmons, Ellora N Karmarkar, et al.
Scientific Reports|February 9, 2020
HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine RegimensXiaoying Shen, Fatima Laher, Zoe Moodie, et al.
Medrxiv : the Preprint Server for Health Sciences|November 1, 2024
Safety and implementation of a phase 1 randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newbornsAvy Violari, Kennedy Otwombe, William Hahn, et al.
Cell Host & Microbe|September 13, 2019
A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV ChallengeAmarendra Pegu, Bhavesh Borate, Yunda Huang, et al.
Frontiers in Immunology|April 10, 2026
Profiling of SARS-CoV-2 virus shedding, antibody neutralization, and T-cell receptor repertoires in a large, multi-center cohort of young adults with varied prior exposuresAndrew Fiore-Gartland, Koshlan Mayer-Blackwell, James Stray, et al.
The Lancet. HIV|October 3, 2020
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyLindsey R Baden, Daniel J Stieh, Michal Sarnecki, et al.
Nature Communications|November 28, 2023
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01Yunda Huang, Lily Zhang, Shelly Karuna, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2006
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialNina D Russell, Barney S Graham, Michael C Keefer, et al.
Ebiomedicine|February 2, 2024
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trialMaurine D Miner, Allan deCamp, Nicole Grunenberg, et al.
Plos Medicine|November 15, 2017
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialKenneth H Mayer, Kelly E Seaton, Yunda Huang, et al.
Pageof 56